Literature DB >> 20367131

Double umbilical cord blood transplant: more than a cell dose?

Anfisa Stanevsky1, Avichai Shimoni, Ronit Yerushalmi, Arnon Nagler.   

Abstract

Cord blood transplant (CBT) is characterized by the limited amount of hematopoietic stem cells (HSCs), and exhibits higher incidence of engraftment failure. Transplant using two (double) CB units (DCBT) is the most promising strategy to date to augment the total transplanted HSC dose. DCBT increases the availability of transplant to adults, for whom there is only a small chance of finding a matched CB suitable for a single unit transplant. Better selection of CB units, optimization of conditioning regimen, and GVHD prophylaxis are important to further improve DCBT outcomes. In this review we attempt to summarize recent progress in the field of DCBT, to present the strategies applied, and to point out directions for the future.

Entities:  

Mesh:

Year:  2010        PMID: 20367131     DOI: 10.3109/10428191003699886

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  9 in total

1.  Towards responsible cord blood banking models.

Authors:  P Rebulla; L Lecchi
Journal:  Cell Prolif       Date:  2011-04       Impact factor: 6.831

2.  Influence of infused cell dose and HLA match on engraftment after double-unit cord blood allografts.

Authors:  Sharon Avery; Weiji Shi; Marissa Lubin; Anne Marie Gonzales; Glenn Heller; Hugo Castro-Malaspina; Sergio Giralt; Nancy A Kernan; Andromachi Scaradavou; Juliet N Barker
Journal:  Blood       Date:  2010-12-13       Impact factor: 22.113

3.  Early CD3 peripheral blood chimerism predicts the long-term engrafting unit following myeloablative double-cord blood transplantation.

Authors:  Laura F Newell; Filippo Milano; Ian B Nicoud; Stacey Pereira; Ted A Gooley; Shelly Heimfeld; Colleen Delaney
Journal:  Biol Blood Marrow Transplant       Date:  2012-02-08       Impact factor: 5.742

4.  Neurotherapeutic effect of cord blood derived CD45+ hematopoietic cells in mice after traumatic brain injury.

Authors:  Hadar Arien-Zakay; Galit Gincberg; Arnon Nagler; Gadi Cohen; Sigal Liraz-Zaltsman; Victoria Trembovler; Alexander G Alexandrovich; Ilan Matok; Hanan Galski; Uriel Elchalal; Peter I Lelkes; Philip Lazarovici; Esther Shohami
Journal:  J Neurotrauma       Date:  2014-07-14       Impact factor: 5.269

Review 5.  Human umbilical cord blood stem cells: rational for use as a neuroprotectant in ischemic brain disease.

Authors:  Hadar Arien-Zakay; Shimon Lecht; Arnon Nagler; Philip Lazarovici
Journal:  Int J Mol Sci       Date:  2010-09-21       Impact factor: 5.923

6.  Acellular bone marrow extracts significantly enhance engraftment levels of human hematopoietic stem cells in mouse xeno-transplantation models.

Authors:  Kazem Zibara; Rima Hamdan; Leila Dib; Steen Sindet-Pedersen; Mohamed Kharfan-Dabaja; Ali Bazarbachi; Marwan El-Sabban
Journal:  PLoS One       Date:  2012-07-02       Impact factor: 3.240

7.  Wnt1 Accelerates an Ex Vivo Expansion of Human Cord Blood CD34(+)CD38(-) Cells.

Authors:  Kamonnaree Chotinantakul; Patcharee Prasajak; Wilairat Leeanansaksiri
Journal:  Stem Cells Int       Date:  2013-08-20       Impact factor: 5.443

8.  Single- or double-unit UCBT following RIC in adults with AL: a report from Eurocord, the ALWP and the CTIWP of the EBMT.

Authors:  Frédéric Baron; Annalisa Ruggeri; Eric Beohou; Myriam Labopin; Mohamad Mohty; Didier Blaise; Jan J Cornelissen; Patrice Chevallier; Guillermo Sanz; Eefke Petersen; Bipin N Savani; Eliane Gluckman; Arnon Nagler
Journal:  J Hematol Oncol       Date:  2017-06-21       Impact factor: 17.388

Review 9.  Umbilical cord blood banking: from personal donation to international public registries to global bioeconomy.

Authors:  Carlo Petrini
Journal:  J Blood Med       Date:  2014-06-18
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.